What’s newsworthy in the Trenton, N.J., and surrounding areas.
A winter storm expected to bring at least a foot of snow to the region has created hazardous conditions and caused flight cancellations. — NYT: Top Stories
TRENTON, N.J. — Looking forward to the next phase of the COVID-19 pandemic response, Mercer County has opened a COVID-19 vaccination facility at CURE Arena in Trenton this week. The vaccination clinic will be a partnership of the CURE Arena with Capital
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced
U.S. Food and Drug Administration assigned a target action date of May 25, 2021 PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License
—New 103,720 ft2 Facility to Serve as Headquarters and House 150 Employees in Cranbury, NJ— —State of the Art R&D Facility to Support Manufacturing Including AAV Drug Product— —cGMP Production to be Initiated in 2021 for Planned Phase 2 Study of First
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies remains under review
PRINCETON, N.J.–(BUSINESS WIRE)–Energy cost savings topped the list for customer needs when considering distributed energy resources (DER) in a recent study by NRG Energy, Inc. (NSYE: NRG) in collaboration with Smart Energy Decisions (SED). The goal of the State of Distributed Energy
Marketing Authorization Application is supported by positive results from the pivotal Phase 3 True North study evaluating oral Zeposia (ozanimod) in adults with moderately to severely active ulcerative colitis If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for